Enoblituzumab is under clinical development by MacroGenics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Enoblituzumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Enoblituzumab (MGA271) is under development for the treatment of neuroblastoma, osteosarcoma, ewing sarcoma, wilms' tumor (nephroblastoma), rhabdomyosarcoma, recurrent head and neck cancer squamous cell carcinoma, non-small cell lung cancer, metastatic melanoma, head and neck cancer squamous cell carcinoma, and prostate cancer. The therapeutic candidate is a monospecific, bivalent humanized IgG1/kappa monoclonal antibody acts by targeting B7-H3.
It was under development for the treatment of solid tumors, transitional cell cancer (urothelial cell cancer), bladder carcnioma, melanoma, squamous non-small cell lung cancer, malignant mesothelioma, thyroid cancer, pancreatic cancer, ovarian cancer, colon cancer, soft tissue sarcoma, triple-negative breast cancer, metastatic renal cell carcinoma, ureter cancer, urethral cancer, prostate cancer and recurrent head and neck cancer squamous cell carcinoma.
MacroGenics is a biopharmaceutical company which focuses on the development and delivery of novel antibody-based therapeutics for the treatment of cancer, infectious diseases and autoimmune disorders. Its product pipeline includes candidates for the treatment of solid tumors, breast and gastroesophageal cancers, type 1 diabetes, HIV, DART product candidates for the treatment of acute myeloid leukemia and myelodysplastic syndrome; and b-cell malignancies. The company’s product candidates are based on proprietary technology platforms, namely, Cancer Stem Cell Platform, Dual-Affinity Re-Targeting (or DART) and TRIDENT Platform and FC Optimization Platform. It works in collaboration with various pharmaceutical and biotechnology companies to leverage its technology platforms and protein engineering capabilities for development. MacroGenics is headquartered in Rockville, Maryland, the US.
For a complete picture of Enoblituzumab’s drug-specific PTSR and LoA scores, buy the report here.